{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:44:05Z","timestamp":1790999045536,"version":"4.1.0"},"reference-count":68,"publisher":"American Association for Cancer Research (AACR)","issue":"7","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012542","name":"Sichuan Provincial Science and Technology Support Program","doi-asserted-by":"publisher","award":["2024YFFK0032"],"award-info":[{"award-number":["2024YFFK0032"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Hepatocellular carcinoma (HCC), a leading cause of global cancer mortality, is characterized by intratumoral heterogeneity, chemoresistance, and limited treatments. Glypican 3 (GPC3), an oncofetal glycoprotein overexpressed in \u223c70% of HCC cases but absent in normal adult tissues, represents an attractive target for antibody\u2013drug conjugates (ADC). To address this unmet need, three GPC3-specific antibodies were developed: a fully human Mab-A with moderate affinity (Kd = 45.7 nmol\/L), recognizing a unique epitope distal to GPC3\u2019s membrane region; a humanized Mab-B with high affinity (Kd = 8.84 nmol\/L), targeting an epitope similar to those of several known therapeutic antibodies; and a biparatopic BpAb-AB with the highest affinity (Kd = 0.383 nmol\/L). Three payloads were used for conjugation: duocarmycin SA (DUBA), pyrrolobenzodiazepine (PBD) dimer, and deruxtecan (Dxd). In cell line\u2013derived xenograft (CDX) models of HCC, DUBA conjugates demonstrated satisfactory efficacy but less potent than other conjugates, whereas PBD dimer conjugates showed potent tumor suppression with narrow therapeutic windows due to dose-limiting toxicity. Mab-B conjugates exhibited comparatively lower efficacy and suboptimal pharmacokinetics. In contrast, Mab-A-Dxd and BpAb-AB-Dxd ADCs produced sustained tumor regression and acceptable safety. Despite lower binding affinity and in vitro activities, Mab-A-Dxd outperformed BpAb-AB-Dxd in vivo, driven by superior tumor penetration, prolonged exposure, and reduced target-mediated drug disposition (TMDD). Efficacy was further validated in patient-derived xenograft (PDX) models. Collectively, the optimized Mab-A-Dxd ADC, engineered with high drug-to-antibody ratio (DAR\u223c10) and Fc-silencing mutations, achieves a favorable balance among tumor penetration, minimized TMDD, and effective GPC3-mediated delivery, positioning it as a promising therapeutic candidate for refractory HCC and other GPC3-expressing malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>We identified Mab-A, a moderate-affinity GPC3 antibody targeting a unique membrane-distal epitope. Combined with a high-DAR (10) Dxd payload and engineered Fc, Mab-A-Dxd shows superior efficacy in CDX\/PDX models, balancing internalization, cytotoxicity, tumor penetration, exposure, and reduced TMDD, redefining ADC design principles and supporting therapeutic potential in HCC and beyond.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-26-0139","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:10:08Z","timestamp":1781637008000},"page":"1665-1680","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development of Glypican 3\u2013Targeting Antibody\u2013Drug Conjugates for Hepatocellular Carcinoma Therapy"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0651-0516","authenticated-orcid":false,"given":"Ning","family":"Li","sequence":"first","affiliation":[{"name":"1Biomedical Innovation and Discovery Center, Salubris (Chengdu) Biotechnology Co., Ltd., Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7672-399X","authenticated-orcid":false,"given":"Yu","family":"Zeng","sequence":"additional","affiliation":[{"name":"1Biomedical Innovation and Discovery Center, Salubris (Chengdu) Biotechnology Co., Ltd., Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4223-5640","authenticated-orcid":false,"given":"Xiaolin","family":"Xiong","sequence":"additional","affiliation":[{"name":"2Department of Pharmacology and Toxicology, Shenzhen Salubris Pharmaceuticals Co., Ltd., Shenzhen, China."},{"name":"3School of Biomedical Engineering, Harbin Institute of Technology (Shenzhen), Shenzhen, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9703-9676","authenticated-orcid":false,"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[{"name":"1Biomedical Innovation and Discovery Center, Salubris (Chengdu) Biotechnology Co., Ltd., Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6521-9318","authenticated-orcid":false,"given":"Xiaolun","family":"Peng","sequence":"additional","affiliation":[{"name":"1Biomedical Innovation and Discovery Center, Salubris (Chengdu) Biotechnology Co., Ltd., Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3510-1843","authenticated-orcid":false,"given":"Wenbin","family":"Chen","sequence":"additional","affiliation":[{"name":"1Biomedical Innovation and Discovery Center, Salubris (Chengdu) Biotechnology Co., Ltd., Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5201-0859","authenticated-orcid":false,"given":"Wen","family":"Wei","sequence":"additional","affiliation":[{"name":"1Biomedical Innovation and Discovery Center, Salubris (Chengdu) Biotechnology Co., Ltd., Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8073-1867","authenticated-orcid":false,"given":"Xiaozhen","family":"Xia","sequence":"additional","affiliation":[{"name":"1Biomedical Innovation and Discovery Center, Salubris (Chengdu) Biotechnology Co., Ltd., Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3625-0625","authenticated-orcid":false,"given":"Ruihong","family":"Liu","sequence":"additional","affiliation":[{"name":"1Biomedical Innovation and Discovery Center, Salubris (Chengdu) Biotechnology Co., Ltd., Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9117-3389","authenticated-orcid":false,"given":"Yao","family":"Lu","sequence":"additional","affiliation":[{"name":"1Biomedical Innovation and Discovery Center, Salubris (Chengdu) Biotechnology Co., Ltd., Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8645-5302","authenticated-orcid":false,"given":"Mengyuan","family":"Geng","sequence":"additional","affiliation":[{"name":"4Biomedical Innovation and Discovery Center, Shenzhen Salubris Pharmaceuticals Co., Ltd., Shenzhen, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8095-1518","authenticated-orcid":false,"given":"Xianqing","family":"Lan","sequence":"additional","affiliation":[{"name":"5Biologics Pharmaceutical R&D Center, Salubris (Chengdu) Biotechnology Co., Ltd., Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9245-5905","authenticated-orcid":false,"given":"Xiuqi","family":"Li","sequence":"additional","affiliation":[{"name":"5Biologics Pharmaceutical R&D Center, Salubris (Chengdu) Biotechnology Co., Ltd., Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3705-8964","authenticated-orcid":false,"given":"Tingting","family":"Yuan","sequence":"additional","affiliation":[{"name":"5Biologics Pharmaceutical R&D Center, Salubris (Chengdu) Biotechnology Co., Ltd., Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6227-4755","authenticated-orcid":false,"given":"Ying","family":"Huang","sequence":"additional","affiliation":[{"name":"5Biologics Pharmaceutical R&D Center, Salubris (Chengdu) Biotechnology Co., Ltd., Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1506-2776","authenticated-orcid":false,"given":"Ying","family":"Xiao","sequence":"additional","affiliation":[{"name":"2Department of Pharmacology and Toxicology, Shenzhen Salubris Pharmaceuticals Co., Ltd., Shenzhen, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8245-6838","authenticated-orcid":false,"given":"Zongchun","family":"Mou","sequence":"additional","affiliation":[{"name":"1Biomedical Innovation and Discovery Center, Salubris (Chengdu) Biotechnology Co., Ltd., Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3935-7114","authenticated-orcid":false,"given":"Junming","family":"Yie","sequence":"additional","affiliation":[{"name":"1Biomedical Innovation and Discovery Center, Salubris (Chengdu) Biotechnology Co., Ltd., Chengdu, China."},{"name":"4Biomedical Innovation and Discovery Center, Shenzhen Salubris Pharmaceuticals Co., Ltd., Shenzhen, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"2026071406015462600_bib1","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1200\/JCO.2025.43.4_suppl.529","article-title":"Hepatocellular carcinoma: a 30-year trend analysis of global burden stratified by risk factors, and socio-demographic indexes","volume":"43","author":"Bhanushali","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026071406015462600_bib2","doi-asserted-by":"publisher","first-page":"102446","DOI":"10.1016\/j.jceh.2024.102446","article-title":"Global epidemiology of hepatocellular carcinoma","volume":"15","author":"Singh","year":"2025","journal-title":"J Clin Exp Hepatol"},{"key":"2026071406015462600_bib3","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1053\/j.gastro.2023.01.033","article-title":"Global epidemiology and genetics of hepatocellular carcinoma","volume":"164","author":"Toh","year":"2023","journal-title":"Gastroenterology"},{"key":"2026071406015462600_bib4","doi-asserted-by":"publisher","first-page":"204","DOI":"10.17998\/jlc.2025.07.25","article-title":"Public health strategies for hepatocellular carcinoma: from risk factors to prevention and control","volume":"25","author":"Lee","year":"2025","journal-title":"J Liver Cancer"},{"key":"2026071406015462600_bib5","doi-asserted-by":"publisher","first-page":"666","DOI":"10.3390\/cancers16030666","article-title":"Management of hepatocellular carcinoma in 2024: the multidisciplinary paradigm in an evolving treatment landscape","volume":"16","author":"Kinsey","year":"2024","journal-title":"Cancers"},{"key":"2026071406015462600_bib6","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.jhep.2025.10.020","article-title":"BCLC strategy for prognosis prediction and treatment recommendations: the 2026 update","volume":"84","author":"Reig","year":"2026","journal-title":"J Hepatol"},{"key":"2026071406015462600_bib7","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"2026071406015462600_bib8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"2026071406015462600_bib9","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.3390\/molecules25122861","article-title":"Antibody-drug conjugates and targeted treatment strategies for hepatocellular carcinoma: a drug-delivery perspective","volume":"25","author":"Dahlgren","year":"2020","journal-title":"Molecules"},{"key":"2026071406015462600_bib10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s12094-021-02707-5","article-title":"Antibody\u2013drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance","volume":"24","author":"Murali","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"2026071406015462600_bib11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jhep.2025.08.018","article-title":"New targets and new drugs for hepatobiliary cancers","volume":"84","author":"Chan","year":"2026","journal-title":"J Hepatol"},{"key":"2026071406015462600_bib12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/s0016-5085(03)00689-9","article-title":"Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma","volume":"125","author":"Capurro","year":"2003","journal-title":"Gastroenterology"},{"key":"2026071406015462600_bib13","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1186\/s40001-024-02073-2","article-title":"The role of glypican-3 in hepatocellular carcinoma: insights into diagnosis and therapeutic potential","volume":"29","author":"Devan","year":"2024","journal-title":"Eur J Med Res"},{"key":"2026071406015462600_bib14","doi-asserted-by":"publisher","first-page":"726","DOI":"10.3390\/cells14100726","article-title":"Unraveling glypican-3: from structural to pathophysiological roles and mechanisms\u2014an integrative perspective","volume":"14","author":"Piao","year":"2025","journal-title":"Cells"},{"key":"2026071406015462600_bib15","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1038\/labinvest.3700479","article-title":"The oncofetal protein glypican-3 is a novel marker of hepatic progenitor\/oval cells","volume":"86","author":"Grozdanov","year":"2006","journal-title":"Lab Invest"},{"key":"2026071406015462600_bib16","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1136\/gut.48.4.558","article-title":"Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders","volume":"48","author":"Zhu","year":"2001","journal-title":"Gut"},{"key":"2026071406015462600_bib17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2147\/jhc.s116513","article-title":"GPC-3 in hepatocellular carcinoma: current perspectives","volume":"3","author":"Wu","year":"2016","journal-title":"J Hepatocellular Carcinoma"},{"key":"2026071406015462600_bib18","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.7150\/jca.39972","article-title":"Glypican-3: a new target for diagnosis and treatment of hepatocellular carcinoma","volume":"11","author":"Guo","year":"2020","journal-title":"J Cancer"},{"key":"2026071406015462600_bib19","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1016\/j.ajpath.2018.05.014","article-title":"Glypican 3 overexpression across a broad spectrum of tumor types discovered with functional genomic mRNA profiling of a large cancer database","volume":"188","author":"Moek","year":"2018","journal-title":"Am J Pathol"},{"key":"2026071406015462600_bib20","doi-asserted-by":"publisher","first-page":"708","DOI":"10.3389\/fonc.2019.00708","article-title":"The role of glypican-3 in regulating Wnt, YAP, and hedgehog in liver cancer","volume":"9","author":"Kolluri","year":"2019","journal-title":"Front Oncol"},{"key":"2026071406015462600_bib21","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.3390\/cancers11091339","article-title":"Glypican 3-targeted therapy in hepatocellular carcinoma","volume":"11","author":"Nishida","year":"2019","journal-title":"Cancers"},{"key":"2026071406015462600_bib22","doi-asserted-by":"publisher","first-page":"80429","DOI":"10.18632\/oncotarget.19035","article-title":"Glypican-3 induces oncogenicity by preventing IGF-1R degradation, a process that can be blocked by Grb10","volume":"8","author":"Cheng","year":"2017","journal-title":"Oncotarget"},{"key":"2026071406015462600_bib23","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.3390\/cancers17243967","article-title":"Prognostic significance of glypican-3 expression in hepatocellular carcinoma treated with atezolizumab-bevacizumab","volume":"17","author":"Kim","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026071406015462600_bib24","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1158\/1078-0432.ccr-12-2616","article-title":"First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma","volume":"19","author":"Zhu","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2026071406015462600_bib25","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00280-017-3241-9","article-title":"Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)","volume":"79","author":"Abou-Alfa","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026071406015462600_bib26","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jhep.2016.04.004","article-title":"Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma","volume":"65","author":"Abou-Alfa","year":"2016","journal-title":"J Hepatol"},{"key":"2026071406015462600_bib27","doi-asserted-by":"publisher","first-page":"eaal4291","DOI":"10.1126\/scitranslmed.aal4291","article-title":"An anti\u2013glypican 3\/CD3 bispecific T cell\u2013redirecting antibody for treatment of solid tumors","volume":"9","author":"Ishiguro","year":"2017","journal-title":"Sci Transl Med"},{"key":"2026071406015462600_bib28","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1158\/1535-7163.mct-24-1049","article-title":"Identification and nonclinical characterization of SAR444200, a novel anti-GPC3 NANOBODY T-cell engager, for the treatment of GPC3+ solid tumors","volume":"25","author":"Meoni","year":"2026","journal-title":"Mol Cancer Ther"},{"key":"2026071406015462600_bib29","doi-asserted-by":"publisher","first-page":"103046","DOI":"10.1016\/j.ctrv.2025.103046","article-title":"CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation","volume":"141","author":"Elahi","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"2026071406015462600_bib30","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1038\/s41423-025-01308-4","article-title":"Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy","volume":"22","author":"Seyhan","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"2026071406015462600_bib31","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.drudis.2013.11.004","article-title":"Antibody\u2013drug conjugates: current status and future directions","volume":"19","author":"Perez","year":"2014","journal-title":"Drug Discov Today"},{"key":"2026071406015462600_bib32","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1242\/jcs.098889","article-title":"LRP1 mediates hedgehog-induced endocytosis of the GPC3-hedgehog complex","volume":"125","author":"Capurro","year":"2012","journal-title":"J Cell Sci"},{"key":"2026071406015462600_bib33","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/protein\/gzw040","article-title":"Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions","volume":"29","author":"Schlothauer","year":"2016","journal-title":"Protein Eng Des Sel"},{"key":"2026071406015462600_bib34","doi-asserted-by":"publisher","first-page":"e0260954","DOI":"10.1371\/journal.pone.0260954","article-title":"Fc-engineered antibodies with immune effector functions completely abolished","volume":"16","author":"Karagiannis","year":"2021","journal-title":"PLoS One"},{"key":"2026071406015462600_bib35","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1080\/14712598.2020.1776255","article-title":"Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy","volume":"21","author":"Hartley","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"2026071406015462600_bib36","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","article-title":"Antibody\u2013drug conjugates: recent advances in linker chemistry","volume":"11","author":"Su","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"2026071406015462600_bib37","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.3390\/pharmaceutics15041132","article-title":"Pharmacokinetics and pharmacodynamics of antibody-drug conjugates administered via subcutaneous and intratumoral routes","volume":"15","author":"Chang","year":"2023","journal-title":"Pharmaceutics"},{"key":"2026071406015462600_bib38","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/hep.30326","article-title":"Glypican-3-specific antibody drug conjugates targeting hepatocellular carcinoma","volume":"70","author":"Fu","year":"2019","journal-title":"Hepatology"},{"key":"2026071406015462600_bib39","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2026071406015462600_bib40","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.2147\/DDDT.S135571","article-title":"Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates","volume":"11","author":"Kalim","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"2026071406015462600_bib41","doi-asserted-by":"publisher","first-page":"508","DOI":"10.3390\/ph15050508","article-title":"Recent advances in translational pharmacokinetics and pharmacodynamics prediction of therapeutic antibodies using modeling and simulation","volume":"15","author":"Haraya","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026071406015462600_bib42","doi-asserted-by":"publisher","first-page":"38696","DOI":"10.1021\/acsomega.5c03755","article-title":"Biological evaluation of cleavable linkers in exatecan-based antibody-drug conjugates: a comparative study of DXd and exo-linker platforms","volume":"10","author":"Watanabe","year":"2025","journal-title":"ACS Omega"},{"key":"2026071406015462600_bib43","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1158\/1535-7163.MCT-23-0359","article-title":"Design and evaluation of phosphonamidate-linked exatecan constructs for highly loaded, stable, and efficacious antibody-drug conjugates","volume":"23","author":"Schmitt","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"2026071406015462600_bib44","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.18632\/oncotarget.6595","article-title":"Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the treatment of lung squamous cell carcinoma","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"2026071406015462600_bib45","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12890-021-01549-9","article-title":"GPC3 affects the prognosis of lung adenocarcinoma and lung squamous cell carcinoma","volume":"21","author":"Ning","year":"2021","journal-title":"BMC Pulm Med"},{"key":"2026071406015462600_bib46","doi-asserted-by":"publisher","first-page":"824208","DOI":"10.3389\/fonc.2022.824208","article-title":"Glypican-3: a novel and promising target for the treatment of hepatocellular carcinoma","volume":"12","author":"Zheng","year":"2022","journal-title":"Front Oncol"},{"key":"2026071406015462600_bib47","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1158\/0008-5472.CAN-10-2277","article-title":"Influence of affinity and antigen internalization on the uptake and penetration of anti-HER2 antibodies in solid tumors","volume":"71","author":"Rudnick","year":"2011","journal-title":"Cancer Res"},{"key":"2026071406015462600_bib48","doi-asserted-by":"publisher","first-page":"e0226593","DOI":"10.1371\/journal.pone.0226593","article-title":"Binding and functional profiling of antibody mutants guides selection of optimal candidates as antibody drug conjugates","volume":"14","author":"Zwaagstra","year":"2019","journal-title":"PLoS One"},{"key":"2026071406015462600_bib49","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1007\/s00262-008-0518-1","article-title":"Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability","volume":"57","author":"Schmidt","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"2026071406015462600_bib50","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1089\/cbr.2009.0627","article-title":"Affinity and avidity in antibody-based tumor targeting","volume":"24","author":"Rudnick","year":"2009","journal-title":"Cancer Biother Radiopharm"},{"key":"2026071406015462600_bib51","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1021\/acs.molpharmaceut.6b00063","article-title":"The interplay of antigen affinity, internalization, and pharmacokinetics on CD44-positive tumor targeting of monoclonal antibodies","volume":"13","author":"Glatt","year":"2016","journal-title":"Mol Pharm"},{"key":"2026071406015462600_bib52","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.3390\/ijms19051435","article-title":"High affinity promotes internalization of engineered antibodies targeting FGFR1","volume":"19","author":"Opali\u0144ski","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2026071406015462600_bib53","doi-asserted-by":"publisher","first-page":"4145","DOI":"10.1158\/0008-5472.can-20-3822","article-title":"Transient competitive inhibition bypasses the binding site barrier to improve tumor penetration of trastuzumab and enhance T-DM1 efficacy","volume":"81","author":"Bordeau","year":"2021","journal-title":"Cancer Res"},{"key":"2026071406015462600_bib54","doi-asserted-by":"publisher","first-page":"eadk1894","DOI":"10.1126\/sciadv.adk1894","article-title":"Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data","volume":"10","author":"Rubahamya","year":"2024","journal-title":"Sci Adv"},{"key":"2026071406015462600_bib55","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1016\/j.apsb.2023.06.015","article-title":"Antibody\u2013drug conjugates: recent advances in payloads","volume":"13","author":"Wang","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"2026071406015462600_bib56","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.pharmthera.2019.04.008","article-title":"Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates","volume":"200","author":"Mahalingaiah","year":"2019","journal-title":"Pharmacol Ther"},{"key":"2026071406015462600_bib57","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026071406015462600_bib58","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1182\/blood.2024024442","article-title":"Antibody-drug conjugate adverse effects can be understood and addressed based on immune complex clearance mechanisms","volume":"144","author":"Taylor","year":"2024","journal-title":"Blood"},{"key":"2026071406015462600_bib59","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/imr.13401","article-title":"Fc gamma receptors: their evolution, genomic architecture, genetic variation, and impact on human disease","volume":"328","author":"Frampton","year":"2024","journal-title":"Immunol Rev"},{"key":"2026071406015462600_bib60","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1158\/1078-0432.ccr-14-2093","article-title":"Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1)","volume":"21","author":"Uppal","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2026071406015462600_bib61","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/abt\/tbab005","article-title":"Mechanisms contributing to ado-trastuzumab emtansine-induced toxicities: a gateway to better understanding of ADC-associated toxicities","volume":"4","author":"Endo","year":"2021","journal-title":"Antibody Ther"},{"key":"2026071406015462600_bib62","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/bctt.s489419","article-title":"Update on pulmonary toxicity induced by new breast cancer treatments","volume":"17","author":"Belluzzi","year":"2025","journal-title":"Breast Cancer Targets Ther"},{"key":"2026071406015462600_bib63","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.1111\/cas.14686","article-title":"Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab\u2013drug conjugate, in monkeys","volume":"111","author":"Kumagai","year":"2020","journal-title":"Cancer Sci"},{"key":"2026071406015462600_bib64","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1158\/0008-5472.can-24-2021","article-title":"Perivascular niche\u2013resident alveolar macrophages promote interstitial pneumonitis related to trastuzumab deruxtecan treatment","volume":"85","author":"Wei","year":"2025","journal-title":"Cancer Res"},{"key":"2026071406015462600_bib65","doi-asserted-by":"publisher","first-page":"102378","DOI":"10.1016\/j.ctrv.2022.102378","article-title":"Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)\u2013related interstitial lung disease\/pneumonitis\u2014focus on proactive monitoring, diagnosis, and management","volume":"106","author":"Swain","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"2026071406015462600_bib66","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11095-021-03158-x","article-title":"Fc\u03b3 receptor-dependent internalization and off-target cytotoxicity of antibody-drug conjugate aggregates","volume":"39","author":"Aoyama","year":"2021","journal-title":"Pharm Res"},{"key":"2026071406015462600_bib67","doi-asserted-by":"publisher","first-page":"6523","DOI":"10.3390\/ijms26136523","article-title":"Antibody\u2013drug conjugates powered by deruxtecan: innovations and challenges in oncology","volume":"26","author":"Jang","year":"2025","journal-title":"Int J Mol Sci"},{"key":"2026071406015462600_bib68","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/imr.13379","article-title":"Living in LALA land? Forty years of attenuating Fc effector functions","volume":"328","author":"Hale","year":"2024","journal-title":"Immunol Rev"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-26-0139\/3803992\/crc-26-0139.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/7\/1665\/3811438\/crc-26-0139.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/7\/1665\/3811438\/crc-26-0139.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T10:01:57Z","timestamp":1784023317000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/7\/1665\/786591\/Development-of-Glypican-3-Targeting-Antibody-Drug"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":68,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-26-0139","relation":{},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}